1. Market Research
  2. > Pharmaceutical Market Trends

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

  • May 2014
  • 153 pages
  • Kelly Scientific Publications
Report ID: 1859471

Summary

Table of Contents

“Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages. The Chinese biopharmaceutical market is presented as follows:

- By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
- By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

- Company financials, sales & revenue figures – historical to Q2-2013
- China GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
- Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Top Five Contract Pharmaceutical Export Markets of China
- Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
- Multinational penetration into the Chinese Pharma Market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top Chinese pharmacos
- Economic indicators, trade policy, merchandise and commercial trade statistics
- Gross Domestic Product of China, historic and projection analysis
- Chinese economic outlook in comparison to advanced economies
- Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
- Prescription drug sales distribution channels in China
- Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

- Amoytop Biotech
- Active Pharmaceutical Products
- Beijing Continent Pharmaceuticals
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Abbott
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson Medical
- Merck
- Novartis
- Pfizer
- Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

- An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
- Knowledge of how the Chinese pharma market will integrate into the global healthcare market
- Information on key regulatory and government policies
- Data on levels of private and publically funded biopharma studies in China
- Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
- International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

Benefits of Investing in our Cutting-Edge Reports:

Clients receive complementary content* with mid-level and enterprise wide licences
Post-sale complementary consultation with senior expert analyst is included
Use of tables and figures in your own reports and presentations is permitted
Each report provides straight-talking strategic analysis & sector intelligence
All reports are updated each quarter to give you the most up-to-date information

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025 Summary Cystic fibrosis (CF), which has been given a the diagnostic code E84 from The International Classification of Diseases, ...

High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global high-content screening (HCS) market is projected to reach USD 909.0 million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are ...

Pharmaceutical Filtration Market by Product (Membrane Filters, Single-Use Systems), Technique (Microfiltration, Ultrafiltration), Application (Final Product Processing, Raw material), Scale of Operation (Manufacturing, Pilot, R&D) - Global Forecast to 202

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global pharmaceutical filtration market is projected to reach USD 22.71 billion by 2021 from USD 13.73 billion in 2016, at a CAGR of 10.6% from 2016 to 2021. Market growth is primarily driven by factors ...

Social Media In Pharma

March 2017 $ 5000

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.